✦ LIBER ✦

Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin

✍ Scribed by Reck, Martin; Thatcher, Nick; Smit, Egbert F.; Lorigan, Paul; Szutowicz-Zielinska, Ewa; Liepa, Astra M.; Winfree, Katherine B.; Peterson, Patrick; Guba, Susan C.; Socinski, Mark A.

Book ID: 119320958
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 525 KB
Volume: 78
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2012.09.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomised phase III trial of carboplati

Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702

✍ Okamoto, H; Watanabe, K; Kunikane, H; Yokoyama, A; Kudoh, S; Shibata, T; Kunitoh 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 130 KB

Induction Pemetrexed and Cisplatin Follo

Induction Pemetrexed and Cisplatin Followed by Maintenance Pemetrexed Versus Carboplatin Plus Paclitaxel Plus Bevacizumab Followed by Maintenance Bevacizumab: A Quality of Life–Oriented Randomized Phase III Study in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer (ERACLE)

✍ Domenico Galetta; Salvatore Pisconti; Saverio Cinieri; Giovanni Luigi Pappagallo 📂 Article 📅 2011 🏛 CIG Media Group, LP. 🌐 English ⚖ 235 KB

Quality of life and survival in patients

Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial

✍ M Helsing; B Bergman; L Thaning; U Hero 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 194 KB